Malignant Hyperthermia Awareness and Training Month – March 1, 2027

Malignant Hyperthermia Awareness and Training Month
Categories:
Tags:
AppreciationAwarenessEducational
Where:
United States
Date change rule:
Every March
Holiday emoji:
🩺

Malignant Hyperthermia Awareness and Training Month takes place throughout March, dedicated to shedding light on this rare, life-threatening genetic disorder. This observance highlights the importance of early diagnosis, understanding triggers, and ensuring healthcare professionals receive critical training to manage MH crises. Learn about symptoms, support research, and advocate for better patient care.

Want to sponsor Malignant Hyperthermia Awareness and Training Month? Learn how

History of Malignant Hyperthermia Awareness and Training Month

Malignant Hyperthermia was an unknown condition back in the early 1960s when it mysteriously took the lives of many patients. The nature of the disease was described as patients experiencing a rapid increase in body temperature while under anesthesia until their bodies could no longer handle it. However, a clearer picture of the disease was given in the mid-1960s when a man from Melbourne, Australia, with a history of family deaths, presented a compound fracture that he had gotten while under anesthesia. Similar cases were reported all around the world since then and in 1966, Dr. Robert A. Gordon named the disease ‘malignant hyperthermia.’ Together with Dr. Beverly Britt, he organized the first symposium on malignant hyperthermia, which was documented and published in the 1966 Canadian Journal of Anesthesiology.

By the mid-1980s, besides a high temperature, symptoms of malignant hyperthermia also included acidosis, muscle rigidity, and breakdown, which is why the treatment of the condition includes dantrolene, a muscle relaxer.

By the late-1980s, a strange observation occurred when a patient with Duchenne muscular dystrophy (D.M.D.) showed symptoms of malignant hyperthermia when anesthetized. Neuroleptic malignant syndrome (N.M.S.) is also another syndrome that displays classic symptoms of malignant hyperthermia.

A major breakthrough in the malignant hyperthermia study happened in 1990 when David MacLennan of the University of Toronto found that pigs were also susceptible to this disease as a result of a special mutation in their genes. Today, scientists all over the world continue their research to further develop ways to prevent and manage malignant hyperthermia.

Malignant Hyperthermia Awareness and Training Month timeline

Early 1960s
The Unknown Condition that Killed Anesthetized Patients

Malignant hyperthermia is still an unknown condition that causes the deaths of patients under anesthesia.

1966
The First Malignant Hyperthermia Symposium

Dr. R. A. Gordona and Dr. B. Britt conduct the first symposium discussing the symptoms of malignant hyperthermia.

1980s
The Symptoms of Malignant Hyperthermia

The symptoms of malignant hyperthermia are determined, which include high temperature, acidosis, and muscle rigidity and breakdown.

2009
Further Findings on the Symptoms

Dr. Susan Hamilton at Baylor University finds that genetically engineered mice with RYR1 develop malignant hyperthermia syndrome after heat exposure.

Malignant Hyperthermia Awareness and Training Month FAQs

When is Malignant Hyperthermia Awareness and Training Month?

In 2027, Malignant Hyperthermia Awareness and Training Month will again be observed throughout March. It’s an annual opportunity to reinforce knowledge about this rare and potentially fatal genetic disorder.

How many people are affected by Malignant Hyperthermia?

While precise numbers vary, MH susceptibility is estimated to occur in about 1 in 2,000 to 1 in 100,000 surgical patients. Awareness campaigns aim to identify more at-risk individuals and prevent adverse events.

What are the common triggers for Malignant Hyperthermia?

The most common triggers for MH are specific inhalation anesthetics and succinylcholine, used during surgery. Recognizing these triggers is crucial for preventing an MH crisis, as avoiding them in susceptible individuals is the primary preventive measure.

Is Malignant Hyperthermia a genetic condition?

MH is indeed a genetic condition, typically inherited in an autosomal dominant pattern. This means that if one parent carries the mutated gene, there’s a 50% chance their child will inherit MH susceptibility, making family history a critical diagnostic tool.

How to Observe Malignant Hyperthermia Awareness and Training Month

  1. Attend symposiums

    The study and development of malignant hyperthermia management is a work in progress. Join symposiums and seminars to get informed about the symptoms and ways to manage this illness.

  2. Join training

    Healthcare professionals are encouraged to attend malignant hyperthermia crisis management training as a way to handle future patients. Find out if you can attend at your local hospital and medical facility to gain a better understanding of the condition.

  3. Donate to non-profit organizations

    Non-profit organizations such as the Malignant Hyperthermia Association of the U.S. (MHAUS,) accept small donations to promote optimum care for patients living with the disease and conduct further research for improved scientific understanding. Any amount could potentially save a life.

5 Important Facts About Malignant Hyperthermia

  1. Malignant hyperthermia is hereditary

    It’s an inherited syndrome that triggers patients who receive general anesthesia.

  2. Dantrolene helps

    The only clinically approved drug that helps relax the muscles of malignant hyperthermia patients, who are experiencing symptoms, is Dantrolene.

  3. Pre-anesthesia assessment

    It’s required for patients to disclose any family history of malignant hyperthermia during a pre-anesthesia assessment.

  4. The onset happens fast

    The symptoms of malignant hyperthermia occur rapidly, requiring healthcare professionals to respond urgently.

  5. Genetic testing is available

    You can find out if you’re susceptible through several genetic testing sites in the country.

Why Malignant Hyperthermia Awareness and Training Month is Important

  1. It raises awareness

    Since malignant hyperthermia is a relatively unknown disease, this month-long observance helps to inform the general public about the condition. Knowledge is key in treating and managing this illness.

  2. It helps research funding

    Continuous research and development for the management of malignant hyperthermia are essential. People showing support through donations tremendously help scientists and researchers to continue with the progress they’ve made in determining the most effective ways to treat this disease.

  3. It makes malignant hyperthermia patients feel seen

    In raising awareness around malignant hyperthermia, patients are less likely to be stigmatized. This eliminates the fear of judgment that they may experience on top of having to deal with the disease.

Malignant Hyperthermia Awareness and Training Month dates

Year Date Day
2027 March 1 Monday
2028 March 1 Wednesday
2029 March 1 Thursday
2030 March 1 Friday
2031 March 1 Saturday